Program Director
Jennifer G. Robinson, MD, MPH
Program Director
Raul D Santos, MD, MSc, PhD
Preventing Atherosclerotic Cardiovascular Disease in Patients with Diabetes Mellitus
The IAS recognizes that system-level improvements are needed in the prevention of ASCVD in patients with diabetes and that progress in CVD risk factor control is slowing. Based on US data, only 14% of patients meet targets for all A1C, BP, lipids, and nonsmoking status. 33-49% of patients still do not meet one or several targets for A1C, blood pressure, or lipids. This problem is exacerbated globally as even fewer meet these targets in many low-and middle-income countries.
The purpose of this video series are to provide a better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focused discussion on statins and newer diabetes drugs.
Each section is introducted by general lecture of the clinical prevalence and evidence. The panel will discuss the real world implications and provide practical implemtation advice.
Pre-activity information
Target Audience
This program is intended for health care professionals management or prevention of ASCVD and specifically those engaged in treating patients diabetes mellitus.
Learning Objectives
At the end of this activity the learner will have:
A better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focus on statins and newer diabetes drugs.
Faculty & Disclosures
Jennifer G. Robinson MD, MPH
| Disclosures | Date of Disclosures |
|---|---|
| Research grants to Institution: Acasti, Amarin, Amgen, Astra Zeneca, Esai, Esperion, Merck, Novartis, Novo-Nordisk, Regeneron, Sanofi, Takeda. | 10-12-2019 |
| Consultant: Amgen, Medicines Company, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi | 10-12-2019 |
Raul D Santos, MD, MSc, PhD
| Disclosures | Date of Disclosures |
|---|---|
| Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron. | 10-12-2019 |
Peter Lansberg, MD, PhD
| Disclosures | Date of Disclosures |
|---|---|
| Unpaid Steering Committee: Kaneka | 10-12-2019 |
| Consultant/Advisory Board: Kaneka, Getz Pharma, Zora, Gendiag. | 10-12-2019 |
| Speaker Bureau: Amgen, Sanofi, Pfizer, Astra-Zeneca, Merck Sharp & Dohme, Getz Pharma; Gendiag | 10-12-2019 |
Philip Barter, MBBS, PhD, FRACP
| Disclosures | Date of Disclosures |
|---|---|
| Consultant/Advisory Board/Speaker Honorarium for Amgen, Pfizer and Sanofi-Regeneron | 10-12-2019 |
Khalid Al-Rasadi, MD
| Disclosures | Date of Disclosures |
|---|---|
| Honoraria for Speakers Bureau: AstraZeneca, Sanofi, Pfizer, Abbott. Advisory Boards: Sanofi, Aegerion. | 10-12-2019 |
Dong Zhao, PhD
| Disclosures | Date of Disclosures |
|---|---|
| Research Grants to Institutions: Astra-Zeneca, Amgen, Boehringer-Ingelheim, Pfizer | 10-12-2019 |
Peter Libby MD
| Disclosures | Date of Disclosures |
|---|---|
| Grant/Research support: Novartis | 10-12-2019 |
| Unpaid Consultant and/or Unpaid Steering or Executive Committee of Clinical Trials: Amgen, AstraZeneca, Esperion, GlaxoSmithKline, Kowa, Merck, Novartis, Pfizer, Sanofi-Aventis-Regeneron | 10-12-2019 |
| Scientific Advisory Board: IFM, Medimmune, DalCor, Amgen, Novartis, Corvidia, Olatec, Xbiotech | 10-12-2019 |
| Dr. Libby declines all personal compensation from pharma or device companies. | 10-12-2019 |
Staff Disclosures
Nothing to disclose.
Funding Information
The International Atherosclerosis Society would like to thank Viatris (formerly Upjohn, a division of Pfizer), for their sponsorship of this education initiative.
CardioMedica (Alexa)
You can also use CardioMedica (an Amazon Alexa skill) to take this Activity
CardioMedica is an education and information channel created for the IAS as an additional way to take education programs using the popular Amazon Alexa device. The programs, offered in English, can be accessed on any Alexa (device or app) using the instructions below.
- First time users: Enable the Skill by saying “Alexa Enable Cardio Medica”
- Once Enabled or Returning Established users: Say , “Alexa Start Cardio Medica“
Tip-After starting the skill the programs will play in order, however, you can also select specific sections from the list below. When Alexa asks you to say “Begin”, just say the catalog number such as “D 1”
For more assistance, visit the CardioMedica page on the AudioEducate(click this link) website
Activity
NAFLD/NASH and ASCVD Connection: Final Messages
Combined Patient Management
Patient Identification and Risk Stratification
ASCVD and NAFLD/NASH: the Background of the Connection
Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?
Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?
Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares
Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA
Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2
Parte 1 – A história na batalha da insulina e glucagon
Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease
Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD
Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient
Part 1: The History in the Battle of Insulin and Glucagon
Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil)
Discusión Foro 4 – Panelist Roopa Mehta (Mexico)
Nuevas terapias para la HF grave – Paola Varleta (Chile)
Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica)